Literature DB >> 17254586

Ethnic differences in the ability of triglyceride levels to identify insulin resistance.

Anne E Sumner1, Catherine C Cowie.   

Abstract

The Metabolic Syndrome is used to predict the onset of coronary artery disease and Type 2 diabetes. As the predictive value of the Metabolic Syndrome has been challenged, alternative syndromes have been developed. All of these syndromes were developed in populations that were predominantly non-Hispanic white (NHW). They include the Enlarged Waist Elevated Triglyceride Syndrome, the Overweight-Lipid Syndrome and the Hypertriglyceridemic Waist Syndrome. The first applies to postmenopausal women, the second to overweight individuals (BMI> or =25 kg/m(2)), and the third to men. Each syndrome uses hypertriglyceridemia as a criterion. However, the definition of hypertriglyceridemia varies by syndrome i.e. TG> or =128 mg/dL for the Enlarged Waist Elevated Triglyceride Syndrome, TG> or =130 mg/dL for the Overweight-Lipid Syndrome, > or =150 mg/dL for the Metabolic Syndrome, and TG> or =176 mg/dL for the Hypertriglyceridemic Waist Syndrome. Insulin resistance and hypertriglyceridemia are highly correlated. But as insulin resistant non-Hispanic blacks (NHB) often have triglyceride (TG) levels below the thresholds set by these syndromes, the ability of either TG or these syndromes to identify high risk NHB is unknown. Using the National Health and Nutrition Examination Survey (NHANES) 1999-2002, our goals were to determine by ethnicity: (1) the prevalence of each of these syndromes; (2) the ability of fasting TG concentrations to identify insulin resistance at cut-off levels established by these syndromes, specifically 130, 150 and 176 mg/dL. Participants were 2804 adults from NHANES 1999-2002. The cohort was divided into tertiles of homeostasis model assessment. Insulin resistance was defined as the upper tertile (> or =2.73). The prevalence of each syndrome was lower in NHB than NHW or Mexican Americans (MA) (all P<0.05). Mean TG levels in NHB, non-Hispanic Whites (NHW) and Mexican Americans (MA) were: 99, 140 and 144mg/dL, respectively. The mean percents of insulin-resistant NHB, NHW and MA with TG<130mg/dL were: 64, 31 and 36. The percents of insulin-resistant NHB, NHW and MA with TG<150mg/dL were: 75, 46 and 47. The percents of insulin-resistant NHB, NHW and MA with TG<176 mg/dL were: 81, 58 and 59. Significance was P<0.001 for each comparison to NHB. In conclusion, the prevalence of syndromes that use TG as a diagnostic criterion is lower in NHB than NHW or MA. NHB are more likely than NHW or MA to be insulin-resistant and have TG levels below threshold values. As syndromes are formulated to identify individuals at high risk for conditions such as cardiovascular disease and Type 2 diabetes, ethnic differences in TG levels should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254586     DOI: 10.1016/j.atherosclerosis.2006.12.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  121 in total

1.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

2.  Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms.

Authors:  Ibiye Owei; Nkiru Umekwe; Jim Wan; Samuel Dagogo-Jack
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-17

3.  Cardiovascular Risk Factors After Adolescent Bariatric Surgery.

Authors:  Marc P Michalsky; Thomas H Inge; Todd M Jenkins; Changchun Xie; Anita Courcoulas; Michael Helmrath; Mary L Brandt; Carroll M Harmon; Mike Chen; John B Dixon; Elaine M Urbina
Journal:  Pediatrics       Date:  2018-01-08       Impact factor: 7.124

4.  Racial/ethnic and sex differences in the relationship between uric acid and metabolic syndrome in adolescents: an analysis of National Health and Nutrition Survey 1999-2006.

Authors:  Mark D DeBoer; Lili Dong; Matthew J Gurka
Journal:  Metabolism       Date:  2011-10-13       Impact factor: 8.694

5.  Ethnic differences in the link between insulin resistance and elevated ALT.

Authors:  Mark D Deboer; R Constance Wiener; Barrett H Barnes; Matthew J Gurka
Journal:  Pediatrics       Date:  2013-08-12       Impact factor: 7.124

Review 6.  Variation in the Calculation of Allostatic Load Score: 21 Examples from NHANES.

Authors:  Michelle T Duong; Brianna A Bingham; Paola C Aldana; Stephanie T Chung; Anne E Sumner
Journal:  J Racial Ethn Health Disparities       Date:  2016-06-28

7.  Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06.

Authors:  Genevieve N Healy; Charles E Matthews; David W Dunstan; Elisabeth A H Winkler; Neville Owen
Journal:  Eur Heart J       Date:  2011-01-11       Impact factor: 29.983

Review 8.  Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes.

Authors:  Yasaman Ghorbani; Katherine J P Schwenger; Johane P Allard
Journal:  Eur J Nutr       Date:  2021-03-02       Impact factor: 5.614

9.  Worse cardiometabolic health in African immigrant men than African American men: reconsideration of the healthy immigrant effect.

Authors:  Michelle Y O'Connor; Caroline K Thoreson; Madia Ricks; Amber B Courville; Francine Thomas; Jianhua Yao; Peter T Katzmarzyk; Anne E Sumner
Journal:  Metab Syndr Relat Disord       Date:  2014-05-09       Impact factor: 1.894

10.  Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007).

Authors:  Alireza Esteghamati; Haleh Ashraf; Omid Khalilzadeh; Ali Zandieh; Manouchehr Nakhjavani; Armin Rashidi; Mehrdad Haghazali; Fereshteh Asgari
Journal:  Nutr Metab (Lond)       Date:  2010-04-07       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.